je.st
news
Tag: results
SunOpta Announces Third Quarter 2014 Results
2014-11-11 23:49:29| Agriculture - Topix.net
SunOpta Inc. , a leading global company focused on natural, organic and specialty foods, today announced financial results for the third quarter ended October 4, 2014. All amounts are expressed in U.S. dollars and results are reported in accordance with U.S. GAAP, except where specifically noted.
Tags: results
quarter
announces
sunopta
Whiting USA Trust (WHX) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
2014-11-11 15:42:29| Steel - Topix.net
Whiting USA Trust issued its quarterly earnings data on Tuesday. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.58 by $0.02, StockRatingsNetwork.com reports.
American Electric Technologies (AETI) Releases Quarterly Earnings Results
2014-11-11 15:38:33| Industrial Machines - Topix.net
American Electric Technologies issued its quarterly earnings data on Tuesday. The company reported earnings per share for the quarter, missing the analysts' consensus estimate of $0.11 by $0.37, Stock Ratings Network reports.
Tags: results
american
releases
technologies
Takata accused in lawsuit of burying bad airbag test results
2014-11-11 15:34:07| Automakers - Topix.net
Takata Corp., the maker of automobile airbags with a potentially lethal defect that prompted the recall of almost 8 million cars, was accused in a lawsuit of a years-long cover-up. The suit in Los Angeles federal court says Takata discovered the flaw in tests about a decade ago and then destroyed records of the study.
Tags: results
test
bad
accused
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients
2014-11-11 14:00:00| Merck.com - Research & Development News
Dateline City: BOSTON Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-nave and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy study (Parts A and B). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
treatment
phase
Sites : [652] [653] [654] [655] [656] [657] [658] [659] [660] [661] [662] [663] [664] [665] [666] [667] [668] [669] [670] [671] next »